# Avalglucosidase Alfa Extension Study

> **NCT02032524** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 19 (actual)

## Conditions studied

- Glycogen Storage Disease Type II Pompe Disease

## Interventions

- **DRUG:** Avalglucosidase Alfa

## Key facts

- **NCT ID:** NCT02032524
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-27
- **Primary completion:** 2022-12-12
- **Final completion:** 2022-12-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032524, "Avalglucosidase Alfa Extension Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02032524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*